바이오테크 보도자료
-
- ReNew Power Announces Its Addition to the World Economic Forum’s Global Lighthouse Network of Companies Leading in the Area of Technology-Enabled, Sustainable Growth
- ReNew Power (“ReNew” or “the Company”), India’s leading renewable energy company, today announced that it has been named to the World Economic Forum’s (WEF) Global Lighthouse Network, which recognizes compan...
- 2021년 03월 16일
-
- Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) ann...
- 2021년 03월 16일
-
- Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector
- Waters Corporation (NYSE:WAT) today released the ACQUITY RDa™ Detector featuring SmartMS™, the company’s newest time-of-flight (TOF) mass spectrometer (MS) for small molecule analysis for pharmaceutical, aca...
- 2021년 03월 16일
-
- Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade[1]
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The...
- 2021년 03월 12일
-
- Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for lanad...
- 2021년 03월 12일
-
- Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenz...
- 2021년 03월 12일
-
- ACLIV Wins ISO 21702 Certification for Killing COVID-19 Virus by 99.9% Within 30 Minutes From Antiviral Testing Agency in France
- NEOTENY, a chemical company specializing in film making, announced that it has received ISO 21702 certification (Certification No.: 21-1634) from an antiviral testing agency in France, confirming that its an...
- 2021년 03월 12일
-
- Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company pioneering condition...
- 2021년 03월 11일
-
- Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-19
- Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA...
- 2021년 03월 10일
-
- Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
- Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application...
- 2021년 03월 08일
-
- TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round
- TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp...
- 2021년 03월 08일
-
- Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives...
- 2021년 03월 08일
전시회
